{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:28:09Z","timestamp":1792718889720,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,7,26]],"date-time":"2007-07-26T00:00:00Z","timestamp":1185408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to describe the prevalence of and risk factors for HIV\u2010associated sensory neuropathy (HIV\u2010SN) in 2006 [the era of stavudine, didanosine and zalcitabine (dNRTI)\u2010sparing highly active antiretroviral therapy (HAART)] and to compare our findings with data obtained in the same clinic in 1993 (pre\u2010HAART) and 2001 (frequent use of dNRTI\u2010containing HAART).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a cross\u2010sectional comparative study using convenience sampling. HIV\u2010positive adults attending a tertiary referral clinic over a 2\u2010week period were screened for HIV\u2010SN using the AIDS Clinical Trials Group screening tool. HIV\u2010SN was defined as present if the patient had both neuropathic symptoms and abnormal signs. Demographic, clinical, laboratory and treatment data were considered as possible risk factors for HIV\u2010SN, and results were compared with data obtained in the same clinic in 1993 and 2001.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred patients were screened. The prevalence of HIV\u2010SN was 42%, which was unchanged since 2001 (44%) despite a significant reduction in the use of dNRTIs. HIV\u2010SN remained much more common than in 1993 (42% vs 13%; <jats:italic>P<\/jats:italic>&lt;0.0001). The only independent associations with HIV\u2010SN in 2006 were increasing patient age and a history of exposure to either stavudine or indinavir. This compares with 1993 when neuropathy was increased in those with <jats:italic>Mycobacterium avium<\/jats:italic> complex infection, and 2001 when patient age and use of stavudine and didanosine were the independent associations with HIV\u2010SN in this clinic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HIV\u2010SN remained common among ambulatory patients in 2006 (42% prevalence) despite a significant reduction in the use of dNRTIs. In addition to patient age and stavudine exposure, indinavir use may be a risk factor for HIV\u2010SN.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2007.00478.x","type":"journal-article","created":{"date-parts":[[2007,7,26]],"date-time":"2007-07-26T10:28:54Z","timestamp":1185445734000},"page":"367-373","source":"Crossref","is-referenced-by-count":91,"title":["Prevalence of and risk factors for HIV\u2010associated neuropathy in Melbourne, Australia 1993\u20132006"],"prefix":"10.1111","volume":"8","author":[{"given":"K","family":"Smyth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JS","family":"Affandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JC","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bowtell\u2010Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AM","family":"Mijch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IJ","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SL","family":"Wesselingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CL","family":"Cherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,7,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200211080-00002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1988.00520330023005"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.5.794"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410230510"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.61.6.606"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1993.00540020045016"},{"key":"e_1_2_6_8_2","first-page":"33","article-title":"An analysis of factors associated with HIV\u2010related peripheral neuropathy","volume":"2","author":"Woolley I","year":"1997","journal-title":"Neurol Infect Epidemiol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.3.607"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90283-8"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJM199005103221901","article-title":"2\u2032, 3\u2032\u2010dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS\u2010related complex. A phase I trial","volume":"322","author":"Lambert J","year":"1990","journal-title":"N Engl J Med"},{"key":"e_1_2_6_12_2","first-page":"21","article-title":"2\u2032, 3\u2032\u2010didehydro\u20103\u2032\u2010deoxythymidine (d4T) in patients with AIDS or AIDS\u2010related complex","volume":"167","author":"Browne M","year":"1993","journal-title":"a phase I trial"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.10.1892"},{"key":"e_1_2_6_14_2","first-page":"816","article-title":"Sensory neuropathy in human immunodeficiency virus\/acquired immunodeficiency syndrome patients","volume":"59","author":"Pettersen J","year":"2006","journal-title":"protease inhibitor-mediated neurotoxicity"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000120622.91018.EA"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.546"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000203336.12114.09"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/426076"},{"key":"e_1_2_6_19_2","unstructured":"National Centre in HIV Epidemiology and Clinical Research.HIV\/AIDS viral hepatitis and sexual transmissible infections in Australia Annual Surveillance Report 2005. National Centre in HIV Epidemiology and Clinical Research University of New South Wales Sydney; Australian Institute of Health and Welfare Canberrahttp:\/\/web.med.unsw.edu.au\/nchecr\/surv_anrep.html2005."},{"key":"e_1_2_6_20_2","unstructured":"CherryC McArthurJ CostelloK WoolleyI MijchA WesselinghS.Increasing prevalence of neuropathy in the era of highly active antiretroviral therapy (HAART).9th Conference on Retroviruses and Opportunistic Infections. Seattle WA February 2002 [Abstract 69]."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000187119.33075.41"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204010-00010"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907090-00015"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00288.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10645"},{"key":"e_1_2_6_26_2","unstructured":"FormaF LiechtyC SelbergPet al. Early clinical toxicity to nonnucleoside reverse transcriptase inhibitor\u2010based HAART in a home\u2010based AIDS care program in rural Uganda.13th Conference on Retroviruses and Opportunistic Infections. Denver CO February 2006 [Abstract 142]."},{"key":"e_1_2_6_27_2","unstructured":"KimA Ngan'gaL MachariaDet al. Adverse events in HIV\u2010infected patients receiving ART in a treatment program in a Nairobi slum Kenya 2003\u201305.13th Conference on Retroviruses and Opportunistic Infections. Denver CO February 2006 [Abstract 143]."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199815000-00005"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000171409.38490.48"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309050-00022"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2007.00478.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2007.00478.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T03:33:51Z","timestamp":1696908831000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2007.00478.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,26]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1468-1293.2007.00478.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2007.00478.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,26]]}}}